

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 2958903 T3**

(12)

Oversættelse af
europæisk patentskrift

(51) Int.Cl.: **C 07 D 295/096 (2006.01)**

(45) Oversættelsen bekendtgjort den: **2017-05-15**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2017-04-12**

(86) Europæisk ansøgning nr.: **14705524.8**

(86) Europæisk indleveringsdag: **2014-02-20**

(87) Den europæiske ansøgnings publiceringsdag: **2015-12-30**

(86) International ansøgning nr.: **EP2014053313**

(87) Internationalt publikationsnr.: **WO2014128207**

(30) Prioritet: **2013-02-22 US 201361767883 P** **2013-02-22 DK 201300104**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Danmark**

(72) Opfinder: **RUHLAND, Thomas, Møllehusene 15, 4000 Roskilde, Danmark**
CHRISTENSEN, Kim Lasse, Holmstrupvej 73, 4200 Slagelse, Danmark

(74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Rued Langgaards Vej 8, 2300 København S, Danmark**

(54) Benævnelse: **FREMGANGSMÅDE TIL FREMSTILLING AF VORTIOXETIN**

(56) Fremdragne publikationer:
WO-A1-03/029232

DK/EP 2958903 T3

DESCRIPTION

Field of invention

[0001] The present invention relates to a process for the manufacture of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine or pharmaceutically acceptable salts thereof.

Background of the invention

[0002] International patent applications including WO 03/029232 and WO 2007/144005 disclose the compound 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine and pharmaceutically acceptable salts thereof. WHO has since published that vortioxetine is the recommended International Non-proprietary Name (INN) for 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine was formerly referred to in the literature as Lu AA21004. FDA and EMA have since approved vortioxetine for the treatment of depression under the trade name Brintellix™.

[0003] Vortioxetine is a 5-HT₃, 5-HT₇, and 5-HT_{1D} receptor antagonist, 5-HT_{1B} receptor partial agonist, 5-HT_{1A} receptor agonist and inhibitor of the 5-HT transporter. Additionally, vortioxetine has demonstrated to enhance the levels of the neurotransmitters serotonin, noradrenalin, dopamine, acetylcholine and histamine in specific areas of the brain. All of these activities are considered to be of clinical relevance and potentially involved in the mechanism of action of the compound [J.Med.Chem., 54, 3206-3221, 2011; Eur. Neuropsychopharmacol., 18(suppl 4), S321, 2008; Eur. Neuropsychopharmacol., 21(suppl 4), S407-408, 2011; Int. J. Psychiatry Clin Pract. 5, 47, 2012].

[0004] Vortioxetine has in clinical trials shown to be a safe and efficacious treatment for depression. A paper reporting the results from a proof-of-concept study to evaluate the efficacy and tolerability of the compound in patients with major depressive disorder (MDD) authored by Alvares *et al* was made available on-line by Int. J. Neuropsychopharm. 18 July 2011. The results from the six weeks, randomised, placebo-controlled study with approximately 100 patients in each arm show that vortioxetine separates significantly from placebo in the treatment of depressive and anxious symptoms in patients with MDD. It is also reported that no clinically relevant changes were seen in the clinical laboratory results, vital signs, weight, or ECG parameters. Results from a long-term study also show that vortioxetine is effective in preventing relapse in patients suffering from MDD [Eur. Neuropsychopharmacol. 21(suppl 3), S396-397, 2011]. A study in elderly depressed patients reported in Int. Clin. Psychopharm., 27, 215-227, 2012 shows that vortioxetine may be used to treat cognitive dysfunctions.

[0005] The manufacturing process used to prepare vortioxetine disclosed in WO 03/029232 is based on solid-phase synthesis and exploits di-arene iron-assisted nucleophilic aromatic substitution reactions in a multistep process. In summary, 4-[piperazine-1-yl]carboxyloxymethyl]phenoxymethyl polystyrene was reacted with a di-arene iron salt, i.e. η^6 -1,2-dichlorobenzene- η^5 -cyclopentadienyliron(II) hexafluorophosphate followed by isolation and washing of the resin and further reaction with 2,4-dimethylthiophenol. Finally, the thus obtained resin was treated with 1,10-phenanthroline and light to de-complex cyclopentadienyliron. The overall yield was low, only 17%. A similar process is disclosed in WO 01/49678 wherein phenoxyphenylpiperazines are prepared as intermediates.

[0006] Di-arene iron compounds have been known for long time, exemplified by ferrocene which consists of two pentadienyl rings bound to iron in a sandwich structure. These compounds have proved to be useful tools in the preparation of e.g. heterocyclic compounds. As an example, Pearson *et al* in J.Org.Chem. 61, 1297-1305, 1996 disclose displacement of chloro atoms from 1,4-dichlorobenzene-cyclopentadienyl-iron (II) by cyclic secondary amines, e.g. piperazine. Interestingly, this reaction results in a symmetric displacement, i.e. displacement of both chloro atoms from the benzene moiety. Sutherland *et al* in J.Heterocyclic Chem., 19, 801-803, 1982 disclose that both chloro atoms in 1,2-dichlorobenzene-cyclopentadienyl-iron(II) are displaced by substituted 1,2-dithiophenol to obtain the corresponding thiaanthrenes. Pearson *et al* [J.Org. Chem., 59, 4561-4570, 1994] disclose the use of 1,4-dichlorobenzene- cyclopentadienyl-iron(II) hexafluorophosphate in the manufacture of asymmetric compounds in which the two chloro atoms are substituted by phenoxy and morpholine, respectively. Notably, the two substitutions require very different reaction conditions and isolation of the intermediate, mono-substituted compound was required. Ruhland *et al* in J. Org. Chem., 67, 5257-5268, 2002 disclose synthesis of 1,2-disubstituted benzenes where selective substitution with different substitutions of the chemically identical chloro atoms is achieved via cyclopentadienyl activation in solid phase.

[0007] Solid-phase chemistry is not feasible for pharmaceutical production involving manufacturing in ton-scale. The massive

handling of resins that would be required and the costs associated are prohibitive. Additionally, the low yield obtained for vortioxetine (only 17%) makes this manufacturing route unattractive.


[0008] Large scale manufacturing of vortioxetine has been disclosed in WO 2007/144005 and WO 2010/094285. Piperazine, 2,4-dimethylthiophenol and 1,2-dihalogenbenzene are mixed e.g. in toluene together with a palladium catalyst to afford vortioxetine. Although this reaction provides high yield and can be handled in large scale, it requires the use of an expensive catalyst, i.e. palladium. Moreover, the reaction conditions are harsh employing elevated temperatures to obtain a satisfactory result, i.e. reflux temperatures or 80-120°C and the use of strong base.

[0009] The present invention provides a manufacturing process for vortioxetine which uses inexpensive starting materials, which can be run at mild conditions and which gives high yields.


Summary of the invention

[0010] The present inventors have found that 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine (vortioxetine) or pharmaceutically acceptable salts thereof can be prepared in a reaction in which a suitable di-arene iron salt, i.e. optionally substituted 1,2-dihalogenbenzene-cyclopentadienyl-iron(II) salt is reacted with piperazine and 2,4-dimethylthiophenol(ate) followed by de-complexation of optionally substituted cyclopentadienyl iron to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. A desired pharmaceutically acceptable salt may be obtained by subsequent reaction with a suitable acid.

[0011] Accordingly, in one embodiment the invention provides a process for the manufacture of vortioxetine or pharmaceutically acceptable salts thereof, which process comprises reacting a compound of formula I




wherein each Hal independently represents fluoro or chloro; R' represents H or R' represents one or two moieties independently selected from CHO, COOH, COOR^{'''} or COONR₂^{'''}, or R' represents one to five moieties independently selected from C₁₋₆-alkyl; R^{'''} independently represents H or C₁₋₆-alkyl; and X⁺ represents a non-coordinating and non-nucleophilic anion, with piperazine of formula II




wherein R represents H,

and with a compound of formula III



wherein R'' represents H or a cation and a base as required in a solvent to obtain a compound of formula IV



[IV]

followed by a de-complexation step in which the optionally substituted cyclopentadienyliron is de-complexed to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine, i.e. vortioxetine.

[0012] The compound of formula I, the compound of formula II and the compound of formula III may be added to the reaction mixture in any sequence or simultaneously.

Figures

[0013] Figure 1: Schematic depiction of a flow chemistry set-up for the reaction of the present invention. Compound of formula I is mixed with compound of formula II and compound of formula III to obtain vortioxetine following de-complexation and deprotection as required.

Detailed description of the invention

[0014] The compound of formula I comprises a di-halogen substituted benzene moiety which is η^6 -bound to the metal centre of a cyclopentadienyl fragment. Said halogen is independently selected from fluoro and chloro. In one embodiment, the halogens are identical; in particular both halogens are chloro. In this embodiment, the di-arene iron compound can be made from very inexpensive starting materials, i.e. 1,2-di-chlorobenzene.

[0015] R' represents H or R' represents one or two moieties independently selected from CHO, COOH, COOR'' or COONR₂'', or R' represents one to five moieties independently selected from C₁₋₆-alkyl; R'' independently represents H or C₁₋₆-alkyl. In one embodiment, R' represent one C₁₋₆-alkyl, such as methyl. In one embodiment, R' is hydrogen, i.e. the cyclopentadienyl moiety is unsubstituted. In one embodiment, R'' represents methyl.

[0016] If properly selected, an acid may provide a desired pharmaceutically acceptable salt of vortioxetine in one step. The use of aqueous HBr may achieve the HBr salt of vortioxetine in one step. The reaction of the present invention run with non-protected piperazine which is beneficial due the reduced number of process steps and thus inherent simplicity.

[0017] In the present context, the term "C₁₋₆-alkyl" is intended to indicate a straight, branched and/or cyclic saturated hydrocarbon containing 1-6 carbon atoms which alkyl may be substituted. Examples include methyl, ethyl, isopropyl, cyclopentyl and 2-cyclopropyl-ethyl.

[0018] In the present context, the term "aryl" is intended to indicate an optionally substituted carbocyclic aromatic hydrocarbon

[0019] R'' represents either hydrogen or a cation which may be either organic or inorganic. Inorganic cation include metal-ion, such as a mono-valent or di-valent metal-ion, such as K⁺, Na⁺, Li⁺ and Mg⁺⁺. Examples of organic cation include 2-hydroxyethyl-trimethylammonium and 1-butyl-3-methylimidazolium. The reaction of the present invention runs best if 2,4-dimethyl thiolate is present. This may be achieved e.g. by adding the thiolate salt (R'' represents cation) to the reaction mixture, or by adding the thiophenol compound (R'' represents H) and a suitable base as required to obtain the corresponding thiolate. A suitable mixture of thiophenol, thiolate and a base may also be used. The process of the present invention does not require harsh basic conditions, and bases typically applied in process chemistry may be applied. Examples of useful bases include K₂CO₃, NaOEt, NaO(t-Bu), KO(t-Bu), NaOH, KOH and NaH.

[0020] X- represents a non-coordinating and non-nucleophilic anion. In the present context a non-coordinating anion is intended to indicate an anion that essentially does not establish a coordinating bond to the iron in the compound of formula I or formula III. In the present context a non-nucleophilic anion is intended to indicate an anion that essentially does not substitute Hal in the compound of formula I. Typical examples include BF_4^- , PF_6^- , ClO_4^- , $[\text{B}[3,5-(\text{CF}_3)_2\text{C}_6\text{H}_3]_4]^-$, $\text{B}(\text{C}_6\text{F}_5)_4^-$ and $\text{Al}(\text{OC}(\text{CF}_3)_3)_4^-$. The use of PF_6^- has the advantage that PF_6^- salts of the compound of formula I are easily isolated and stored. This means that the compound of formula I may be prepared in a process which is separated in time and place from the process of the present invention.

[0021] A wide range of solvents may be applied in the process of the present invention. Useful examples include toluene, THF (tetrahydrofuran), MTBE (methyl *tert*-butyl ether), water, ethanol, 2-propanol, NMP (N-methyl-2-pyrrolidone), DMF (dimethylformamide), MIBK (methylisobutyl ketone), TEA (triethyl amine), DIPEA (N,N-diisopropylethylamine), DCM (dichloromethane), ethylacetate, isopropylacetate and combinations of these.

[0022] The optionally substituted cyclopentadienyl-iron fragment is removed in a decomplexation step. This step is well-known from the literature and can be achieved in various ways. *J.Heterocycl.Chem.*, 19, 801-803, 1982 discloses that decomplexation can be achieved by pyrolysis at 200-250°C; *J.Org.Chem.*, 67, 5257-5268, 2002 and *J.Polymer.Sci.*, 35, 447-453, 1997 apply photolysis in the presence of CH_3CN and 1,10-phenanthroline; and *Chem. Soc. Perkin Trans I.*, 197-201, 1994 discloses the use of potassium *tert*-butoxide at elevated temperatures in high-boiling solvents, such as pyridine or DMSO. Photolysis which is also known as photodissociation or photodecomposition is a chemical reaction where a chemical bond is broken upon irradiation with light. For the reaction of the present invention, de-complexation by photolysis may conveniently be carried out under irradiation with light in the visible or near UV spectrum.

[0023] The manufacture of compound of formula I used in the present invention is known from literature. *J.Org.Chem.*, 67, 5257-5268, 2002 discloses a process in which 1,2-dichlorobenzene, anhydrous aluminium trichloride, aluminium powder and ferrocene are reacted at 95°C followed by aqueous work-up and treatment with ammonium hexafluorophosphate. Compounds of formula I where X- represents a anion different from hexafluorophosphate may be obtained in a similar way by means of a different and appropriate salt, e.g. ammonium BF_4^- . If suitably substituted ferrocene is used, compound of formula I wherein R' is different from H may be obtained.

[0024] 2,4-Dimethyl-thiophenol, salts thereof and piperazine are all well-known compounds and readily available in large quantities.

[0025] The compound of formula III may for example be obtained from the corresponding arylbromide or arylchloride, i.e. 1-bromo-2,4-dimethyl-benzene or 1-chloro-2,4-dimethyl-benzene in a Grignard-type reaction where said compound is reacted with Mg followed by elemental sulfur to obtain a compound of formula III where R" represent MgCl^+ or MgBr^+ .

[0026] An advantage of the process of the present invention is that it runs at low temperature, such as ambient temperature, e.g. 15-30°C. The reaction of the present invention, however, runs both at much higher and much lower temperatures as long as the solvent(s) chosen is sufficiently fluid at the temperature (and pressure) used. In one embodiment, the temperature is between -25°C and 140°C, such as between 0°C and 100°C. In one embodiment the temperature is between 10°C and 80°C, such as 15°C-50°C.

[0027] Pharmaceutically acceptable salts are intended to indicate acid addition salts of acids that are non-toxic. Said salts include salts made from organic acids, such as maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanesulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Said salts may also be made from inorganic acids, such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Particular mention is made of salts made from hydrobromic acid and lactic acid. Distinct mention is made of the hydrobromide acid salt.

[0028] In one embodiment, 1 equivalent of a compound of formula I is mixed with a compound of formula II (1-5 equivalents, such as 1-3 equivalents), a compound of formula III (1-5 equivalents, such as 1-3 equivalents) in a solvent together with a base as needed (more than 0.5 equivalent, such as between 0.5 and 20 equivalents, such as 1-5 equivalents), e.g. at 10-50°C, such as 15-25°C to obtain a compound of formula IV. The compound of formula IV is then de-complexed, e.g. by photolysis to obtain vortioxetine. A pharmaceutically acceptable salt may be obtained by further reaction with an appropriate acid. It may also be

feasible to de-protect piperazine as required prior to de-complexation.

[0029] In one embodiment, 1 equivalent of a compound of formula I is mixed with a base (more than 0.5 equivalent, such as between 0.5 and 20 equivalents, such as 1-5 equivalents) and piperazine (1-5 equivalents, such as 1-3 equivalents) in a solvent. The mixture is stirred (e.g. at 10-50°C, such as 15-25°C) and 2,4-dimethyl thiophenol (1-5 equivalents, such as 1-3 equivalents) is added and the reaction is stirred to obtain a compound of formula IV. The compound of formula IV is then de-complexed, e.g. by photolysis to obtain vortioxetine. A pharmaceutically acceptable salt may be obtained by further reaction with an appropriate acid.

[0030] In one embodiment, 1 equivalent of η^6 -1,2-dichlorobenzene- η^5 -cyclopentadienyliron(II) hexafluorophosphate is mixed with 1-5 equivalent base and piperazine (1-3 equivalent, such as 2 equivalents) in a solvent, such as THF/water. After stirring, 2,4-dimethylthiophenol (1-3 equivalent, such as 2 equivalents) is added and the mixture obtained is stirred to obtain the compound of formula IV, e.g. at 10°C-50°C. Votioxetine is obtained by de-complexation, e.g. by photolysis.

[0031] De-complexation by photolysis may be carried out e.g. in batch mode or in flow mode. De-complexation may conveniently be carried out in the following way. The reaction mixture comprising the compound of formula IV is mixed with aqueous acid (e.g. aqueous HCl) and organic impurities are optionally removed e.g. by addition of an immiscible organic solvent, such as *n*-heptane, followed by phase separation. The phase containing the compound of formula IV obtained above is passed through an irradiated glass tube where photolysis occurs to obtain vortioxetine. As an example, the aqueous phase may be circulated through an irradiated glass tube.

[0032] Alternatively, the compound of formula I may be prepared and used immediately in the process of the present invention without isolation. For example 1,2-dichlorobenzene (2-20 equivalents, such as 3-6 equivalents) is mixed with a suitably substituted ferrocene (1 equivalent), aluminium chloride (0.1-2 equivalent, such as 0.2-1 equivalent) and fine aluminium powder (0.01-0.5 equivalent, such as 0.05-0.2 equivalent) and heated to 80-120°, such as 100-110° to obtain a compound of formula I. The compound of formula I may then be further reacted as described above to obtain vortioxetine.

[0033] The process of the present invention may be run in batch mode, wherein the reactants are added to a vessel or container. Alternatively, the process of the present invention is amenable to flow chemistry wherein the reactants are mixed and pumped through tubes wherein the reaction takes place. Figure 1 depicts a schematic flow set-up for the reaction of the present invention. The reaction of the present invention may also be carried out partly in batch mode and partly in a flow set-up.

[0034] In one embodiment, the invention relates to vortioxetine and pharmaceutically acceptable salts thereof manufactured by a process of the present invention.

[0035] As demonstrated in the examples, the present invention provides a non-resin based manufacturing process for vortioxetine and pharmaceutically acceptable salts thereof in which an asymmetric displacement of two identical halogen atoms from a symmetric reactant (1,2-dihalogenbenzene) is effected in a one-pot synthesis, i.e. without the need for isolation of intermediates, such as intermediates where only one halogen is substituted. The process of the present invention avoids the use of expensive reactants and catalysts; it can be run at low temperatures and generally at mild conditions. Thus, simple and inexpensive manufacturing equipment can be applied, and the risk of unwanted side-reactions is minimized. High yields and high purity are achieved, and the process of the present invention is well-suited for industrial scale.

[0036] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the phrase "the compound" is to be understood as referring to various compounds of the invention or particular described aspect, unless otherwise indicated.

[0037] The description herein of any aspect or aspect of the invention using terms such as "comprising", "having," "including," or "containing" with reference to an element or elements is intended to provide support for a similar aspect or aspect of the invention that "consists of", "consists essentially of", or "substantially comprises" that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).

Examples

Example 1

[0038] η^6 -1,2-Dichlorobenzene- η^5 -cyclopentadienyliron(II) hexafluorophosphate (25 g, 61 mmol), potassium carbonate (16.7 g, 121 mmol) and piperazine (10.3 g, 120 mmol) was dissolved in a mixture of THF (200 mL) and water (50 mL). The reaction mixture was stirred for 1 h at ambient temperature. To the reaction mixture was added 2,4-dimethyl thiophenol (8.8 g, 63.7 mmol) and stirring was continued overnight.

[0039] The reaction mixture was poured into aqueous hydrochloric acid (2 M, 200 mL) over a period of 20 min. To the mixture was added *n*-heptane (15 mL) and the phases were separated. The organic phase was extracted once with water (15 mL). The THF/water phase was circulated at room temperature through an irradiated glass spiral (100 W incandescent light). During this step water and THF separated and only the lower water phase was pumped through the photolysis equipment, and the liberated 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine concentrated in the upper THF phase.

[0040] After complete de-complexation, the phases were separated and the water phase was extracted twice with THF (2 x 70 mL). The combined THF phases were diluted with toluene (50 mL) and subsequently washed twice with aqueous sodium hydroxide solution (1.0 M, 50 mL and 30 mL).

[0041] The organic phase was separated, and the THF was removed at 40 °C at reduced pressure. The resulting solution was added slowly to a mixture of aqueous hydrobromic acid (48 w/w %, 7.0 mL, 62 mmol), water (20 mL) and toluene (10 mL) at 40 °C. The desired 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine HBr was isolated by filtration. The filter cake was washed with toluene (40 mL) and water (10 mL) yielding 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine HBr (13.3 g, 35.0 mmol 64.1 %) as a white powder.

Al 1 ppm, Fe 401 ppm, Na 291 ppm, P 2453 ppm (as determined by ICP-AES).

Purity: Area %: Vortioxetine 99.73, 1-[2-(3,5-dimethyl-phenylsulfanyl)-phenyl]-piperazine 0.08%, unknowns 0.19 (as determined by GC).

¹H NMR (DMSO-d6): 8.84 (bs, 2H), 7.34 (d, 1H, 7.7 Hz), 7.26 (s, 1H), 7.16 (m, 2H), 7.11 (dd, 1H, 7.8 and 1.7 Hz), 6.97 (dd, 1H, 7.8 and 1.7 Hz), 6.41 (dd, 1H, 7.8 and 1.3 Hz), 3.26 (brm, 4H), 3.20 (brm, 4 H), 2.33 (s, 3H), 2.25 (s, 3H).

Crystal form: β -form (as determined by XRPD). Please see WO 2007/144005 for definition of the α -form and β -form of vortioxetine HBr.

Water content: <0.1 % (as determined by Karl Fisher) and <0.2 % (as determined by thermo gravimetric analysis).

Elemental analysis C₁₈H₂₃N₂SBr requires C 56.99 H 6.11 N 7.38, found C 57.10, H 6.12, N 7.26.

Example 2

[0042] 1,2-Dichloro benzene (158.4 g, 1.08 mol), ferrocene (40.6 g, 218 mmol), aluminium trichloride (13.8 g, 104 mmol) and fine aluminium powder (7.0 g, 26 mmol) were mixed and heated at 110 °C for 6 h. The reaction mixture was cooled to 25 °C and added slowly to a mixture of ice (240 g) and *n*-heptane (100 mL) over 25 minutes. (CAUTION: the treatment of unreacted aluminium trichloride with water is highly exothermic).

[0043] The mixture was treated with Celite 545® (14 g) and stirred at ambient temperature for 20 minutes prior to filtration. The filter cake was washed with water (15 mL). The filtrates were combined, and the phases were separated. The water phase was washed with toluene (2 x 50 mL). To the water phase was slowly added aqueous sodium hydroxide (10.8 M, 70 mL, 0.76 mol) until the pH was 6.5. The precipitated aluminium oxides was removed by filtration, and the filter cake was washed with water (25 mL).

[0044] The collected aqueous phases was added to a mixture of potassium carbonate (20 g, 0.14 mol) and piperazine (9.4 g, 0.11 mol) in THF (100 mL) and stirred for 3 hours at ambient temperature. To this mixture was added 2,4-dimethyl thiophenol (8.9 g, 64 mmol) and stirring was continued overnight.

[0045] The reaction mixture was poured slowly into aqueous hydrochloric acid (4.0 M, 130 mL, 0.52 mol). The reaction mixture was pumped through an irradiated glass tube (100 W incandescent light). During this step water and THF separated and only the lower water phase was pumped through the photolysis equipment, and the liberated 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine concentrated in the upper THF phase.

[0046] After complete de-complexation the phases were separated and the water phase was extracted twice with toluene (2 x 70

mL). The combined organic phases was washed with sodium hydroxide (1.0 M, 70 mL, 70 mmol) and then with water (25 mL). The THF was removed at 40 °C at reduced pressure. The toluene solution was added slowly to a mixture of aqueous hydrobromic acid (48 w/w %, 7.5 mL, 67 mmol), water (20 mL) and toluene (10 mL) at 35 °C. 4-[2-(2,4-Dimethyl-phenyl-sulfanyl)-phenyl]-piperazine HBr was isolated by filtration. The filter cake was washed with toluene (40 mL) and water (10 mL) yielding 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine HBr (7.3 g, 19.2 mmol, 8.8 % from ferrocene) as an off-white powder.

Al 6 ppm, Fe 18 ppm, Na 3 ppm, P 7 ppm (as determined by ICP-AES)

Purity: Area %: Vortioxetine 99.96, 1-[2-(3,5-dimethyl-phenylsulfanyl)-phenyl]-piperazine 0.04, unknown 0 % (as determined by GC)

¹H NMR (DMSO-d6): 8.86 (bs, 2H), 7.34 (d, 1H, 7.7 hz), 7.26 (s, 1H), 7.16 (m, 2H), 7.11 (d, 1H, 7.9), 6.97 (dd, 1H, 7.8 and 1.8 hz), 6.41 (dd, 1H, 7.7 and 1.4 hz), 3.27 (bm, 4H), 3.21 (bm, 4 H), 2.33 (s, 3H), 2.25 (s, 3H).

Crystal form: Mixture of α and β -form (as determined by XRPD).

Water content: 0.14% (as determined by Karl Fisher) and <0.2% (as determined by thermo gravimetric analysis).

Elemental analysis C₁₈H₂₃N₂SBr requires C 56.99 H 6.11 N 7.38, found C 56.94, H 6.09, N 7.31.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- [WO20029232A \[0002\] \[0005\]](#)
- [WO2007144005A \[0002\] \[0009\] \[0041\]](#)
- [WO0149678A \[0005\]](#)
- [WO2010094285A \[0008\]](#)

Non-patent literature cited in the description


- J.Med.Chem., 2011, vol. 54, 3206-3221 [\[0003\]](#)
- Eur. Neuropsychopharmacol., 2008, vol. 18, 4S321- [\[0003\]](#)
- Eur. Neuropsychopharmacol., 2011, vol. 21, 4407-408 [\[0003\]](#)
- Int. J. Psychiatry Clin Pract., 2012, vol. 5, 47 [\[0003\]](#)
- Int. J. Neuropsychopharmacol., 2011, [\[0004\]](#)
- Eur. Neuropsychopharmacol., 2011, vol. 21, 3396-397 [\[0004\]](#)
- Int. Clin. Psychopharmacol., 2012, vol. 27, 215-227 [\[0004\]](#)
- **PEARSON et al.** J.Org.Chem., 1996, vol. 61, 1297-1305 [\[0006\]](#)
- **SUTHERLAND et al.** J.Heterocyclic Chem., 1982, vol. 19, 801-803 [\[0006\]](#)
- **PEARSON et al.** J.Org. Chem., 1994, vol. 59, 4561-4570 [\[0006\]](#)
- **RUHLAND et al.** J. Org. Chem., 2002, vol. 67, 5257-5268 [\[0006\]](#)
- J.Heterocycl.Chem., 1982, vol. 19, 801-803 [\[0022\]](#)
- J.Org. Chem, 2002, vol. 67, 5257-5268 [\[0022\]](#)
- J.Polymer.Sci., 1997, vol. 35, 447-453 [\[0022\]](#)
- Chem. Soc. Perkin Trans I., 1994, 197-201 [\[0022\]](#)
- J.Org.Chem, 2002, vol. 67, 5257-5268 [\[0023\]](#)

Patentkrav


1. Fremgangsmåde til fremstillingen af vortioxetin eller farmaceutisk acceptable salte deraf, hvilken fremgangsmåde omfatter at reagere en forbindelse af formel I




hvor hver Hal uafhængigt repræsenterer fluor eller chlor; R' repræsenterer H eller R' repræsenterer en eller to grupper uafhængigt valgt fra CHO, COOH, COOR'' eller COONR₂'', eller R' repræsenterer en til fem grupper uafhængigt valgt fra C₁₋₆-alkyl; R'' uafhængigt repræsenterer H eller C₁₋₆-alkyl; og X⁻ repræsenterer en ikke-koordinerende og ikke-nukleofil anion, med piperazin af formel II



hvor R repræsenterer H,
og med en forbindelse af formel III



15 hvor R'' repræsenterer H eller en kation og en base som krævet i et solvent for at opnå en forbindelse af formel IV



efterfulgt af et de-komplekseringstrin i hvilket den eventuelt substituerede cyclopentadienyliron de-komplekseres, for at opnå 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin (vortioxetin).

5

2. Fremgangsmåden ifølge krav 1, hvor Hal repræsenterer chlor.

3. Fremgangsmåden ifølge krav 1 eller 2, hvor R' repræsenterer hydrogen.

10 **4.** Fremgangsmåden ifølge et hvilket som helst af kravene 1-3, hvor X- vælges fra PF_6^- , AlCl_4^- , ClO_4^- , BF_4^- , $[\text{B}[3,5-(\text{CF}_3)_2\text{C}_6\text{H}_3]_4]^-$, $\text{B}(\text{C}_6\text{F}_5)_4^-$ og $\text{Al}(\text{OC}(\text{CF}_3)_3)_4^-$.

5. Fremgangsmåden ifølge krav 4, hvor X- er PF_6^- .

15 **6.** Fremgangsmåden ifølge et hvilket som helst af kravene 1-5, hvor solventet er valgt fra toluen, THF (tetrahydrofuran), MTBE (methyltertiær-butylether), vand, ethanol, 2-propanol, NMP (N-Methyl-2-pyrrolidon), DMF (dimethylformamid), MIBK (methylisobutylketon), TEA (triethylamin), DIPEA (N,N-diisopropylethylamin), DCM (dichloromethan), ethylacetat, isopropylacetat og
20 kombinationer af disse.


7. Fremgangsmåden ifølge et hvilket som helst af kravene 1-6, hvor R" repræsenterer H.

8. Fremgangsmåden ifølge et hvilket som helst af kravene 1-7, hvor de-
5 komplekseringstrinnet omfatter fotolyse.

9. Fremgangsmåden ifølge krav 1, hvor 1 ækvivalent af en forbindelse af formel I blandes med en forbindelse af formel II (1-5 ækvivalenter) og en forbindelse af formel III (1-5 ækvivalenter) i et solvent sammen med en base som krævet
10 (mere end 0,5 ækvivalent) for at opnå en forbindelse af formel IV efterfulgt af de-
kompleksering for at opnå 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin.

10. Fremgangsmåden ifølge krav 1, hvor 1 ækvivalent af en forbindelse af forbindelse af formel I blandes med en base (mellem 0,5 og 20 ækvivalenter),
15 piperazin (1-5 ækvivalenter) og 2,4-dimethyl thiophenol (1-5 ækvivalenter) i et solvent for at opnå en forbindelse af formel IV, efterfulgt af de-kompleksering for at opnå 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin.

11. Fremgangsmåden ifølge krav 1, hvor 1 ækvivalent af η^6 -1,2-dichlorbenzen- η^5 -
20 cyclopentadienyliron(II) hexafluorophosphat blandes med 1-5 ækvivalent base, 1-3
ækvivalenter 2,4-dimethylthiophenol og 1-3 ækvivalenter piperazin i et solvent
ved 10 °C til 50 °C for at opnå forbindelsen af formlen



efterfulgt af de-kompleksering for at opnå 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin.

12. Fremgangsmåden ifølge et hvilket som helst af kravene 1-11, hvor det
5 opnåede 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin reageres med en
egnet syre for at opnå det ækvivalente farmaceutisk acceptable salt.

DRAWINGS

Figure 1

